Noonan syndrome-associated myeloproliferative disorder with somatically acquired monosomy 7: impact on clinical decision making

Br J Haematol. 2019 Nov;187(4):E83-E86. doi: 10.1111/bjh.16191. Epub 2019 Oct 15.

Mattias Hofmans^{1

2}, Rieke Schröder³, Tim Lammens^{1

4}, Christian Flotho^{3

5}, Charlotte Niemeyer^{3

5}, Nadine Van Roy^{4

6}, Wim Decaluwe⁷, Jan Philippé^{2

4}, Barbara De Moerloose^{1

4}

¹ Division of Paediatric Haematology-Oncology and Stem Cell Transplantation, Department of Paediatrics, Ghent University Hospital, Ghent, Belgium.
² Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.
³ Division of Paediatric Haematology and Oncology, Department of Paediatrics and Adolescent Medicine, Medical Centre, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
⁴ Cancer Research Institute Ghent, Ghent University, Ghent, Belgium.
⁵ German Cancer Consortium, Partner Site Freiburg, German Cancer Research Centre, Heidelberg, Germany.
⁶ Centre for Medical Genetics, Ghent University, Ghent, Belgium.
⁷ Department of Paediatrics, Neonatal Intensive Care, AZ Sint-Jan Bruges, Bruges, Belgium.

No abstract available

Keywords: azacitidine; juvenile myelomonocytic leukaemia; methylation analysis; monosomy 7; noonan syndrome-associated MPD.

Publication types